PR88868

SHANGHAI, April 6, 2021 /PRNewswire=KYODO JBN/ --

Shanghai Genechem Co., Ltd. (Genechem), a discovery company dedicated to novel

drug target discovery and development of novel therapeutics, today announced

the execution of a global collaboration with I-Mab (Nasdaq: IMAB), a

Nasdaq-listed global biopharmaceutical company, to develop and commercialize

multiple bi-specific antibodies (BsAb) based on monoclonal antibody developed

by Genechem and antibodies selected by I-MAB.  

"This collaboration is the first of many that will leverage Genechem's Good

Research Practice (GRP) and CHAMP antibody discovery platform, strong

bioinformatic database, as well as strong development expertise of synergistic

partners, to deliver globally competitive assets based on innovative targets.

We are excited to collaborate with I-Mab, a global leader in Oncology and

antibody development, to bring more products to address clinical unmet needs

for patients in China and globally", commented Yueqiong Cao, Founder and CEO of

Genechem.

About Shanghai Genechem Co., Ltd. (Genechem)

Genechem is a leading innovation research company focused on target

discovery/validation, development of antibody and cell therapy products against

novel targets, and partnership globally to maximize its portfolio. Founded in

2002, now with over 500 employees, Genechem works closely with Research

Oncologists to translate clinical research into therapeutics addressing high

clinical unmet needs, leveraging its strong network of Research Oncologists in

over 300 hospitals and Good Research Practice (GRP platform) which includes

comprehensive RNAi library, tools including genetic typing, bioinformatic

analysis, genetic manipulation, as well as SOP and project management systems.

For more information, visit http://www.gcbio.com/.

Contact:

Dr. Tong Zhang

Chief Business Officer

Shanghai Genechem Co., Ltd

Tong.zhang@genechem.com.cn

+86-18501607878

Source: Shanghai Genechem Co., Ltd. (Genechem)